Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia Reports Strong Q1 2026 Financials and Key Pipeline Progress

Idorsia Ltd announced strong financial results for Q1 2026, driven by a 74% year-on-year increase in QUVIVIQ net sales to CHF 44 million. The company also reported outstanding Phase 2 results for daridorexant in pediatric insomnia, showing significant efficacy and excellent safety. Idorsia is expanding QUVIVIQ's global reach and co-promotion efforts while advancing its pipeline, including the planned Phase 3 initiation for lucerastat in Fabry disease and progress in several immunology programs. Partnering discussions for TRYVIO/JERAYGO are also ongoing, contributing to the company's focus on accelerating growth and unlocking value.

• Robust QUVIVIQ Commercial Performance and Global Expansion: QUVIVIQ net sales surged by 74% to CHF 44 million in Q1 2026, reflecting strong uptake across North America and Europe. The drug is now available in 13 countries, with further market introductions planned and new strategic commercial alliances established in Latin America and the Middle East to accelerate its trajectory toward blockbuster status.
• Positive Pediatric Daridorexant Phase 2 Results: Idorsia reported outstanding Phase 2 results for daridorexant in children with insomnia disorder, demonstrating a statistically significant dose-dependent response on total sleep time and clinically meaningful improvements in sleep measures. The study also confirmed excellent safety and tolerability, paving the way for regulatory discussions and scientific publications.
• Advancing a Diverse Pipeline: The company is on track to initiate a Phase 3 program for lucerastat, a potential first oral therapy for Fabry disease, in mid-2026. Additionally, proof-of-concept studies for first-in-class oral CCR6, CXCR7, and CXCR3 receptor antagonists are progressing, targeting autoimmune conditions, CNS inflammation, multiple sclerosis, and immuno-dermatology disorders, with results expected later in 2026.

Expanding Daridorexant's Clinical Reach Beyond Core Insomnia

Daridorexant is being investigated across multiple therapeutic areas beyond its primary insomnia indication, with emerging evidence supporting its potential in neurological and psychiatric conditions. These investigations range from controlled clinical studies to retrospective analyses, exploring both symptomatic relief and potential disease-modifying effects.

• Alzheimer's Disease - Dual orexin receptor antagonists including daridorexant represent a promising strategy for AD management through stabilizing sleep parameters and potential neuroprotective effects, with clinical studies supporting their use in patients with AD and comorbid sleep-wake rhythm disorders, though further investigation is needed to explore broader implications in modifying neurodegeneration

• Substance Use Disorders - An observational, retrospective study of 41 outpatients treated with daridorexant 50 mg daily for three months demonstrated significant improvements in sleep outcomes, psychopathology, quality of life, and craving, with a 65.8% abstinence rate and generally safe tolerability profile showing only mild, transient drowsiness in 21.1% of patients

• Comorbid Insomnia and Obstructive Sleep Apnoea (COMISA) - Post hoc analysis from Phase 3 studies evaluated daridorexant 25 mg and 50 mg in patients with untreated mild OSA and comorbid insomnia, demonstrating improvements in wake after sleep onset, latency to persistent sleep, subjective total sleep time, and Insomnia Daytime Symptoms and Impacts Questionnaire scores, with the 50 mg dose showing superior efficacy across all sleep parameters

Targeting Unmet Needs in the Evolving Insomnia Landscape

The pharmaceutical industry is increasingly focusing on specific vulnerable populations and addressing critical gaps in insomnia management identified over the past three years. Research has revealed significant disparities in treatment access and awareness, particularly around evidence-based therapies like Cognitive Behavioral Therapy for Insomnia (CBT-I). Multiple underserved populations have emerged as priority targets requiring tailored therapeutic approaches.

Vulnerable and Underserved Populations:
• Military veterans experiencing insomnia rates nearly double that of civilian populations, with complex interactions between sleep disturbances, substance use, and perceived stress requiring specialized intervention strategies
• Migrant older adults in rapidly urbanizing areas showing higher loneliness scores (mean 8.58) compared to local older adults (mean 8.00), representing an emerging vulnerable demographic in global urbanization contexts
• Female cancer survivors, particularly breast and gynecological cancer patients, where poor sleep quality reaches 62% in breast cancer survivors—three times more frequent than the general population
• Older adults with multiple comorbidities facing complex diagnostic challenges due to polypharmacy, age-related sleep changes, and the intertwined nature of sleep disturbances with existing medical conditions
• Persons living with dementia and their caregivers, where sleep disturbances accelerate cognitive decline, increase institutionalization rates, and require specialized intervention approaches

Critical Treatment Access and Awareness Gaps:
• Low public recognition of CBT-I despite its first-line recommendation, with patients substantially more familiar with pharmacological treatments than behavioral therapies
• Significant accessibility barriers to CBT-I due to resource demands and shortage of trained professionals capable of delivering this evidence-based intervention
• Racial and gender disparities limiting access to effective therapies, resulting in medication overuse among certain populations and clinical biases in prescribing patterns
• Geographic and socioeconomic barriers preventing equitable access to specialized sleep medicine services and evidence-based treatments

Clinical Practice Implementation Challenges:
• Gap between scientific guidelines and real-world practice in elderly insomnia management, with pharmacological treatment often becoming chronic and deviating from clinical recommendations
• Insufficient implementation of benzodiazepine receptor agonist deprescribing in routine clinical care despite known safety risks in older populations
• Fragmented care coordination and poor communication hindering follow-up and continuity of care across healthcare settings
• Limited patient involvement in shared decision-making despite its recognized importance for treatment adherence and outcomes

Personalized Medicine and Phenotype-Specific Needs:
• Heterogeneity in patient presentation requiring personalized approaches tailored to insomnia phenotypes, particularly regarding objective sleep duration (< 6 hours vs ≥ 6 hours)
• Differential treatment response assessment needs between CBT-I versus pharmacotherapy based on specific insomnia phenotypes and comorbidity profiles
• Comorbid pain management requiring additional interventions specifically addressing pain in older adults with chronic insomnia to facilitate successful treatment engagement

Idorsia's Dual Strategy: Insomnia Momentum and Pipeline Re-evaluation

Idorsia's latest financial update paints a picture of a company strategically navigating both established and emerging therapeutic areas. The standout performance of QUVIVIQ (daridorexant), a dual orexin receptor antagonist, with a 74% surge in net sales, firmly establishes its presence in the insomnia market. This success is not merely about sales figures; it reflects the growing acceptance of DORAs, a class of drugs that inhibit wakefulness rather than inducing sedation, offering a more physiological approach to sleep management with benefits like no evidence of rebound insomnia or withdrawal, and little to no abuse potential. The positive Phase 2 results for daridorexant in pediatric insomnia further underscore its potential, opening a significant new market segment and reinforcing its differentiated profile. However, ongoing vigilance regarding post-marketing safety signals, including potential sleep-related psychiatric symptoms and suicide risk, remains crucial for sustained market confidence.

In its pipeline, the planned Phase 3 initiation for lucerastat in Fabry disease represents a continued commitment to rare diseases. As a substrate reduction therapy, lucerastat aims to address the underlying pathology by reducing glycosphingolipid accumulation. While the Phase 3 MODIFY trial did not meet its primary endpoint of neuropathic pain, the observed significant reduction in plasma globotriaosylceramide (Gb3) is a compelling pharmacodynamic signal. This suggests that while pain may not be the most responsive clinical endpoint, the drug is biologically active. Future development may need to pivot, potentially focusing on other Fabry manifestations, such as renal function, where long-term substrate reduction could offer meaningful clinical benefit. This necessitates a careful re-evaluation of clinical trial design and endpoints to unlock lucerastat's full potential.

Furthermore, Idorsia's active pursuit of partnering discussions for TRYVIO/JERAYGO (aprocitentan) highlights a pragmatic strategy to maximize the value of an approved asset. Aprocitentan, a novel endothelin receptor antagonist for resistant hypertension, addresses a significant unmet medical need. Its approval, based on efficacy in lowering blood pressure and proteinuria with an improved safety profile compared to earlier ERAs, makes it an attractive asset. Strategic alliances can accelerate its global reach and impact, while also mitigating the inherent risks of launching a novel therapy in a competitive market. This multi-pronged approach, balancing successful commercialization, data-driven pipeline advancement, and strategic collaborations, positions Idorsia for continued growth and value creation.